Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Novo Nordisk will pay $300 million upfront to Jiangsu Hengrui Pharmaceuticals for rights to experimental GLP-1 pill HRS-1596, with Hengrui eligible for milestone payments up to $2.3 billion. Novo gets development, manufacturing and commercialization rights outside Taiwan, Macao, Hong Kong and mainland China and plans g
Novo Nordisk OMXCOP:NOVO_B will pay $300 million upfront to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental GLP-1 pill, the Chinese drugmaker said on Tuesday.The deal gains Novo a further potential revenue stream in the booming weight loss market, which analysts expect…